As have been demonstrated in some in vitro experiments, Rituximab promotes the sensitivity of some drug-resistant lymph cells to chemotherapy drugs as well as induction of apoptosis of DHL-4 B lymph cells.

• 体外研究发现rituximab可使呈药物抵抗性的人体淋巴细胞对一些化疗药物的细胞毒性敏感，并且可导致DHL-4人B淋巴细胞株凋亡。 1997年11月，美罗华(rituximab)作为第一种单克隆抗体药物被FDA批准用于临床治疗。